Emcure Pharmaceuticals Limited (NSE:EMCURE)

Market Cap	258.53B
Revenue (ttm)	78.96B
Net Income (ttm)	6.81B
Shares Out	189.51M
EPS (ttm)	36.43
PE Ratio	37.45
Forward PE	n/a
Dividend	3.00 (0.21%)
Ex-Dividend Date	n/a

Volume	76,316
Average Volume	188,657
Open	1,402.50
Previous Close	1,409.60
Day's Range	1,351.10 - 1,419.00
52-Week Range	889.00 - 1,580.00
Beta	n/a
RSI	63.28
Earnings Date	Aug 5, 2025

About Rover Group

Emcure Pharmaceuticals Limited engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. It offers products in various therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV antivirals, respiratory, gastrointestinal, pain and analgesics, blood related, oncology/anti-neoplastics, anti-diabetic, hormones, neurology/central nervous system, dermatology, and other areas, as well as vitamins, minerals, and nutrients. The company also develops products across various platforms, including chiral mol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 10,852
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: EMCURE

Financial Performance

In 2024, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.